JP2015083582A5 - - Google Patents

Download PDF

Info

Publication number
JP2015083582A5
JP2015083582A5 JP2014247793A JP2014247793A JP2015083582A5 JP 2015083582 A5 JP2015083582 A5 JP 2015083582A5 JP 2014247793 A JP2014247793 A JP 2014247793A JP 2014247793 A JP2014247793 A JP 2014247793A JP 2015083582 A5 JP2015083582 A5 JP 2015083582A5
Authority
JP
Japan
Prior art keywords
suspension
less
volume
suspension according
gauge needle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014247793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015083582A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015083582A publication Critical patent/JP2015083582A/ja
Publication of JP2015083582A5 publication Critical patent/JP2015083582A5/ja
Pending legal-status Critical Current

Links

JP2014247793A 2008-11-16 2014-12-08 高濃度の低粘度懸濁液 Pending JP2015083582A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11508008P 2008-11-16 2008-11-16
US61/115,080 2008-11-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011536414A Division JP5711138B2 (ja) 2008-11-16 2009-11-10 高濃度の低粘度懸濁液

Publications (2)

Publication Number Publication Date
JP2015083582A JP2015083582A (ja) 2015-04-30
JP2015083582A5 true JP2015083582A5 (enExample) 2015-07-02

Family

ID=42170660

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011536414A Expired - Fee Related JP5711138B2 (ja) 2008-11-16 2009-11-10 高濃度の低粘度懸濁液
JP2014247793A Pending JP2015083582A (ja) 2008-11-16 2014-12-08 高濃度の低粘度懸濁液

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011536414A Expired - Fee Related JP5711138B2 (ja) 2008-11-16 2009-11-10 高濃度の低粘度懸濁液

Country Status (7)

Country Link
US (2) US8779094B2 (enExample)
EP (1) EP2376522A4 (enExample)
JP (2) JP5711138B2 (enExample)
KR (1) KR20110103961A (enExample)
CA (1) CA2743789C (enExample)
IL (1) IL212919A (enExample)
WO (1) WO2010056657A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2717154T3 (es) 2007-06-22 2019-06-19 Univ Texas Formación de partículas de péptido o proteína submicrométricas estables mediante congelación de película fina
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CN103096934A (zh) * 2010-03-09 2013-05-08 詹森生物科技公司 非水性高浓度低粘度混悬剂
US9445990B2 (en) * 2010-10-06 2016-09-20 Medtronic, Inc. TNF inhibitor formulation for use in implantable infusion devices
US20120230913A1 (en) * 2011-03-10 2012-09-13 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
AU2012328524B2 (en) * 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
EP3854433A3 (en) 2011-11-07 2021-10-27 Battelle Memorial Institute Processes for delivery of viscous drug therapies
NZ701915A (en) * 2012-05-18 2016-11-25 Genentech Inc High-concentration monoclonal antibody formulations
HK1220120A1 (zh) * 2013-03-15 2017-04-28 Ansun Biopharma, Inc. 制造注射蛋白质微粒悬浮液的方法
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
CN103976947B (zh) * 2014-06-05 2016-08-17 段明星 一种含酶油悬浮剂及其制备方法与应用
WO2016054259A1 (en) * 2014-10-01 2016-04-07 Arsia Therapeutics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
JP5774190B1 (ja) * 2014-12-12 2015-09-09 ジーンメディカル株式会社 皮下注射用剤及び皮下注射用剤を含有する注射器の製造方法
KR102496871B1 (ko) * 2014-12-12 2023-02-07 주식회사 모테조 피하 주사용제
EP3522918A1 (en) * 2016-10-06 2019-08-14 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
AU2017364077A1 (en) 2016-11-22 2019-06-20 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
WO2019023392A1 (en) 2017-07-25 2019-01-31 Elektrofi, Inc. FORMATION OF PARTICLES COMPRISING AGENTS
US12115262B2 (en) 2018-05-24 2024-10-15 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
KR102051808B1 (ko) 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
EP3917500A2 (en) 2019-01-31 2021-12-08 Elektrofi, Inc. Particle formation and morphology
SG11202107901QA (en) 2019-02-05 2021-08-30 Lindy Biosciences Inc Isolated cell culture components and methods for isolating the same from liquid cell culture medium
US20200376128A1 (en) * 2019-06-01 2020-12-03 Lupin Holdings B.V. Monodisperse resorbable polyester polymer compositions, systems, and methods
JP7781743B2 (ja) * 2019-09-13 2025-12-08 エレクトロフィ，インコーポレイテッド 疾患の処置のための治療用生物学的作用剤の送達のための組成物及び方法
AU2021257476A1 (en) 2020-04-17 2022-11-03 Elektrofi, Inc. Methods of forming particles by continuous droplet formation and dehydration

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795516A (fr) 1972-02-17 1973-08-16 Ciba Geigy Preparations de peptides huileuses et injectables et procede pour leur preparation
US4310516A (en) 1980-02-01 1982-01-12 Block Drug Company Inc. Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
EP0079143A3 (en) 1981-10-20 1984-11-21 Adnovum Ag Pseudoplastic gel transfer
US4594108A (en) 1983-09-19 1986-06-10 The Dow Chemical Company Highly pseudoplastic polymer solutions
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5288479A (en) 1989-01-17 1994-02-22 Sterling Drug, Inc. Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof
SE465950B (sv) 1989-10-23 1991-11-25 Medinvent Sa Kombination av ett aggregat partikelformat, kristallint eller frystorkat laekemedel med en pseudoplastisk gel foer beredning av ett injicerbart preparat samt foerfarande foer dess framstaellning
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
YU87892A (sh) 1991-10-01 1995-12-04 Eli Lilly And Company Lilly Corporate Center Injektibilne formulacije produženog otpuštanja i postupci za njihovo dobijanje i primenu
WO1993019739A1 (en) 1992-03-30 1993-10-14 Alza Corporation Viscous suspensions of controlled-release drug particles
US5571525A (en) 1992-03-30 1996-11-05 Alza Corporation Erosion rate modifier for use in bioerodible drug delivery devices and method of use
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
DK0768867T3 (da) 1994-06-13 2002-10-28 Alza Corp Doseringsform til indgivelse af lægemiddel i væskeformig formulering
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
NZ333580A (en) 1996-07-03 2000-06-23 Alza Corp Non-Aqueous protic peptide formulations, preferably LHRH
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
IN184589B (enExample) 1996-10-16 2000-09-09 Alza Corp
US7393630B2 (en) 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
ES2261190T3 (es) 1999-02-08 2006-11-16 Alza Corporation Vehiculos viscosos no acuosos estables de fase unica y formulaciones que utilizan dichos vehiculos.
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
FR2809309B1 (fr) * 2000-05-23 2004-06-11 Mainelab Microspheres a liberation prolongee pour administration injectable
WO2002043580A2 (en) 2000-10-27 2002-06-06 Epic Therapeutics, Inc. Production of microspheres
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
WO2002067991A1 (en) * 2001-02-23 2002-09-06 Genentech, Inc. Erodible polymers for injection
EP1492554B1 (en) * 2001-06-21 2019-08-21 Althea Technologies, Inc. Spherical protein particles
WO2004060343A1 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
CA2540695A1 (en) * 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
EP1646445A4 (en) 2003-07-18 2007-09-19 Baxter Int METHOD OF MANUFACTURING, USING AND COMPOSING SMALL BALLULAR PARTICLES PRODUCED BY CONTROLLED PHASE SEPARATION
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
US8333995B2 (en) 2004-05-12 2012-12-18 Baxter International, Inc. Protein microspheres having injectable properties at high concentrations
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US20070015689A1 (en) 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
EP1968550A2 (en) 2005-12-16 2008-09-17 University Of Kansas Nanoclusters for delivery of therapeutics
WO2007072982A1 (en) 2005-12-20 2007-06-28 Fujifilm Corporation Protein nanoparticles and the use of the same
US20080102128A1 (en) * 2006-07-28 2008-05-01 Flamel Technologies, Inc. Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them
ES2717154T3 (es) * 2007-06-22 2019-06-19 Univ Texas Formación de partículas de péptido o proteína submicrométricas estables mediante congelación de película fina
CN101081882A (zh) * 2007-07-06 2007-12-05 天津大学 大分子印迹交联聚乙烯基吡咯烷酮微球及低温悬浮聚合制备方法
JP2009173610A (ja) 2008-01-28 2009-08-06 Fujifilm Corp タンパク質ナノ粒子
EP2259798B1 (en) 2008-03-05 2013-12-11 Baxter International Inc. Surface-modified particles and methods for targeted drug delivery
BRPI0908686B8 (pt) 2008-05-09 2021-05-25 South Dakota State Univ método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas
US20100009007A1 (en) 2008-07-10 2010-01-14 Baxter International Inc. Non-covalent modification of microparticles and process of preparing same
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado

Similar Documents

Publication Publication Date Title
JP2015083582A5 (enExample)
AR099912A1 (es) Derivados de exendina-4 como agonistas dobles de glp1 / gip o triples de glp1 / gip / glucagon
PH12015502469A1 (en) Fcrn-binding abolished anti-igf-ir antibodies and their use in the treatment of vascular eye diseases
MX2016014414A (es) Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico.
IL285440A (en) Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly
TWD190432S (zh) 鼻管
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
MX381016B (es) Composiciones de nanopartículas para su uso en la entrega de una carga útil al cerebro.
JP2016540026A5 (enExample)
IL269962A (en) Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability
JP2016540030A5 (enExample)
BR112016016932A8 (pt) uso de uma combinação de oxaliplatina (oxa), leucovorina (lv) e 5-fluorouracil (5-fu)
EP3037877A3 (en) A pellicle
TWD174176S (zh) 給藥裝置之部分（二）
WO2015168656A3 (en) Biological complexes and methods for using same
蔡林婷 et al. Effect of three pathogenic Vibrios on the blood biochemical parameters of Pseudosciaena crocea
Isaev et al. The role of presumptions in law
Yan Mobile Internet Era’s Explosive Growth in Full Swing
CN302510909S (zh) 燃油喷射泵(cb6p990)
Goodwyn Broad Strokes of Heresy: Religious Dichotomy in Peter of Les Vaux-De-Cernay’s Historia Albigensis
CN302487912S (zh) 包装瓶
CN302586572S (zh) 无针注射器
CN302570718S (zh) 医用敷料
吴一凡 My Chinese Teacher
潘禹潼 My Bedroom